Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Blocking adhesion molecules with natalizumab in multiple sclerosis].

B Schreiner1, B C Kieseier, H-P Hartung

  • 1Neurologische Klinik und Poliklinik der Julius-Maximilians-Universität Würzburg.

Der Nervenarzt
|April 7, 2005
PubMed
Summary

Natalizumab, a treatment for multiple sclerosis (MS), was withdrawn due to safety concerns including progressive multifocal leukoencephalopathy. Further studies are investigating patient risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The Freiburg concept of the "Neurological Emergency Receiving Team (NERT)" : Concept for structuring of time-critical courses of action for patients with a predominant disability problem with an interdisciplinary and interprofessional emergency team in the nontraumatological resuscitation room].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2026
Same author

Exercise facilitates post-stroke recovery through mitigation of neuronal hyperexcitability via interleukin-10 signaling.

Nature communications·2025
Same author

Autoreactive T cells target peripheral nerves in Guillain-Barré syndrome.

Nature·2024
Same author

Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study.

Multiple sclerosis and related disorders·2022
Same author

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.

Multiple sclerosis (Houndmills, Basingstoke, England)·2021
Same author

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis and related disorders·2020

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Context:

  • Natalizumab is a monoclonal antibody targeting alpha(4)-integrins, crucial for lymphocyte trafficking in autoimmune diseases.
  • It was investigated for multiple sclerosis (MS), inflammatory bowel diseases, and rheumatoid arthritis.
  • Phase III trials (AFFIRM, SENTINEL) assessed natalizumab's efficacy in relapsing-remitting MS.

Purpose:

  • To evaluate the efficacy and safety of natalizumab in treating multiple sclerosis.
  • To update on the clinical trial results and market status of natalizumab.
  • To investigate the risks associated with natalizumab therapy, particularly in combination with interferon beta-1a.

Summary:

  • Natalizumab showed initial promise for MS treatment, leading to FDA authorization based on interim analyses.

Related Experiment Videos

  • However, serious adverse events, including progressive multifocal leukoencephalopathy (PML), led to its market withdrawal in 2005.
  • Ongoing research aims to understand the risks, especially for patients in the Sentinel Study.

    • Impact:

    • The withdrawal of natalizumab highlighted the critical need for rigorous safety monitoring in MS therapeutics.
    • This event underscored the complex risk-benefit balance in treating autoimmune neurological conditions.
    • Further research is essential to determine safe treatment protocols and patient selection for immunomodulatory therapies.